A PYMNTS Company

India: Ranbaxy/Sun deal must be altered, CCI says

By  |  December 1, 2014

The Competition Commission of India has suggested changes to the proposed merger of pharmaceutical giants Sun Pharma and Ranbaxy after the regulator raised concerns about the deal.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The CCI released a report of its review of the $4 billion merger; that report including suggested alterations to the transaction, including possible divestitures, to address competition concerns. While the exact suggestions were not made public, sources say the proposed concessions include the sale of some brands.

    Sun and Ranbaxy have been waiting for CCI approval on their merger, first announced last April. They will now have to respond to the proposed changes before moving forward, say reports.

    Their merger would create India’s largest pharmaceutical company, and thus has attracted significant attention. The deal was also the first merger that faced public scrutiny in India, reports say.

    Full content: NDTV

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.